ArticleBMC medical genomics2025
Expanding the clinical phenotype of DYNC1H1 -associated mutations: a Chinese family with autosomal dominant complex hereditary spastic paraplegia.
Article in BMC medical genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHereditary spastic paraplegias (HSPs) are a clinically and genetically heterogeneous group of neurodegenerative diseases. To date, at least 84 distinct loci (SPGs) and 67 causative genes have been identified. Even though the number of known causative genes is constantly increasing, a substantial portion of patients remains without a molecular diagnosis. Variants in the dynein, cytoplasmic 1, heavy chain 1(DYNC1H1)gene have been reported to cause a range of neurogenetic diseases, including spinal muscular atrophy (SMA), Charcot-Marie-Tooth disease (CMT), and cortical malformations. This study aims to characterize the clinical spectrum of DYNC1H1-related disorders by reporting a rare missense variant (c.13763 C > T, p.Thr4588Met) identified in a Chinese family with autosomal dominant (AD) complex HSP.
methodsThe affected individuals underwent a comprehensive neurological evaluation, including assessment of clinical features, laboratory testing, brain magnetic resonance imaging (MRI), and electrophysiological studies. The repetition/deletions in the SPAST, ATL1 gene were detected using multiplex ligation-dependent probe analysis (MLPA). Whole-exome sequencing (WES) was performed to identify the disease-causing mutation in the proband, which was subsequently validated by Sanger sequencing in the proband and his parents. In silico analysis was performed to predict the pathogenicity of the identified mutations.
resultsA heterozygous missense variant (c.13763 C > T, p.Thr4588Met) in the DYNC1H1 gene was identified, which was classified as likely pathogenic according to ACMG guidelines. The family was affected by autosomal dominant complex HSP, presenting with marked spastic paraplegia and ataxia. In silico analyses (e.g., using PolyPhen-2, PROVEAN, Mutation Taster, and CADD) indicated a deleterious effect on protein function.
conclusionsThis study reports a rare DYNC1H1 variant associated with autosomal dominant (AD) complex HSP, expanding the mutational and phenotypic spectrum of DYNC1H1-related disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.